optima4heart: pharmacological intervention and transition of care in cardiovascular disease management
optima4heart: pharmacological intervention and transition of care in cardiovascular disease management
批准号:
9770702
负责人:
Gabriela Voskerician
金额:
$22.49万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-15 至 2020-03-31
关键词:
AddressAgreementAlgorithmsAmericanAtrial FibrillationCardiologyCardiomyopathiesCardiovascular DiseasesCaringCategoriesCessation of lifeCitiesClinicalCommunicationConfidential InformationCoronary ArteriosclerosisData SetDevelopmentDevicesDiagnosisDiseaseDisease ManagementElectronic Health RecordEpidemicEvaluationFutureGoalsGuidelinesHealthHealth Insurance Portability and Accountability ActHealthcare SystemsHeart failureHypertensionIncidenceIntelligenceInternal MedicineInterventionKansasLogicMedicineMyocardial InfarctionNephrologyOffice VisitsOutcomeOutcome MeasurePatient CarePatient Care ManagementPatient riskPatientsPharmaceutical PreparationsPharmacologyPharmacy facilityPhasePhysiciansProcessProtocols documentationProviderQuality of CareQuestionnairesRecommendationRisk stratificationSeveritiesSoftware ToolsStrokeStructureSurveysSymptomsTestingTimeTreatment ProtocolsTreatment outcomeTrustValidationWalkingWeightWorkadjudicationadverse event riskaugmented intelligencebasecare providersclinical applicationcollegecomputerized data processingdashboarddata exchangeeffective therapyflexibilityimprovedinteroperabilitymultidisciplinarynovelpatient portalresponsestandardized caresuccesssystem architecture
中文摘要
需求:每天有2200名美国人死于心血管疾病(CVD),而9210万人患有心血管疾病
英文摘要
Need: 2,200 Americans die of cardiovascular disease (CVD) each day, while 92.1 million live with
some form of CVD or stroke. Uncontrolled hypertension (HTN), heart failure (HF), coronary artery
disease (CAD), and atrial fibrillation (AFib) represent the primary drivers of the CVD “epidemic”. The
American College of Cardiology (ACC) recommends two critical directions for improving care: (1)
Pharmacological Interventions that drive effective treatment decisions, and (2) Standardization of Care
Flows for cross-communication of treatment protocols amongst providers.
Solution: In response to the ACC guidance (above), Optima Integrated Health aims to build a
clinician-trusted software tool (optima4heart) that recommends: (1) a pharmacological intervention and
(2) needed changes in team-based transfer of care [primary care provider (PCP) ó Cardiologist] for
clinicians managing patients with CVD. optima4heart is clinically applicable through a patient-tailored
analytic intelligence (AI) augmented by a dashboard user-interface display in the electronic health
record (EHR). optima4heart directly addresses the current barriers to progress. It aims to: (1a) address
the evolving complexity of the treatment management guidelines; (1b) unify and harmonize segregated
patient datasets; (2a) provide a clinical organization-integrated approach to pharmacological
interventions; (2b) establish an inter-division protocol for transfer of care. optima4heart is the multi-
disease expansion of optima4BP, an AI solution developed to address pharmacological intervention
management for clinicians treating patients with uncontrolled HTN. optima4heart Aim: Reduce the
incidence of HF, stroke, myocardial infarction (MI)] or death.
Goal of Phase I: Expand the capabilities of optima4BP by building a 2-disease CVD pharmacological
intervention and transfer of care platform that integrates HF with the existing HTN solution.
The Specific Aims are: Aim 1. Develop and Validate the Pharmacological Intervention. optima4BP AI
framework will be adapted to prioritize pharmacological intervention changes that tackle the real-time
dynamic between HF and HTN based on changing patient status. Aim 2. Develop and Validate HF Transfer
of Care. The Transfer of Care will establish whether the patient is stable/unstable leading to a
recommendation in assignment of care (transfer of care, when appropriate). Aim 1 & Aim 2 Validation will be
performed using theoretical patient test cases. Adjudication of optima4heart pharmacological intervention
and transfer of care by a multi-disciplinary clinical team will establish its clinical validity.
Future Work: Phase II will establish a 4-disease CVD pharmacological intervention and transfer of care
platform, expanding HTN + HF to include CAD and AFib. The result: a flexible care management platform
that can adapt to one or any combination of the primary drivers impacting the CVD “epidemic”.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction
-
批准号:10641684
-
项目类别:
-
资助金额:$124.64万
-
财政年份:2022
-
负责人:Gabriela Voskerician
-
依托单位:
PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction
-
批准号:10381898
-
项目类别:
-
资助金额:$103.49万
-
财政年份:2022
-
负责人:Gabriela Voskerician
-
依托单位:
ARTERY Outcomes: tAilored dRug Titration through artificial intElligence: an inteRventional studY
-
批准号:10001603
-
项目类别:
-
资助金额:$65.48万
-
财政年份:2019
-
负责人:Gabriela Voskerician
-
依托单位:
PROTECT: optima4BP 2.0: prediction of Optimal Treatment and Route to achieve and maintain BP Target
-
批准号:10159301
-
项目类别:
-
资助金额:$71.6万
-
财政年份:2018
-
负责人:Gabriela Voskerician
-
依托单位:
PROTECT: optima4BP 2.0: prediction of Optimal Treatment and Route to achieve and maintain BP Target
-
批准号:9901106
-
项目类别:
-
资助金额:$75.02万
-
财政年份:2018
-
负责人:Gabriela Voskerician
-
依托单位:
Tailored Drug Titration through Artificial Intelligence
-
批准号:9341533
-
项目类别:
-
资助金额:$84.9万
-
财政年份:2017
-
负责人:Gabriela Voskerician
-
依托单位:
Personal Mobile Diabetes Management System(PMDMS): IN-TRACK
-
批准号:8311248
-
项目类别:
-
资助金额:$24.42万
-
财政年份:2012
-
负责人:Gabriela Voskerician
-
依托单位:
海外基金